- Home
- BRT vs ATYR Comparison
BRT vs ATYR Comparison
Compare BRT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | ATYR |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.9M | 79.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRT | ATYR |
|---|---|---|
| Price | $14.33 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $19.75 | $8.75 |
| AVG Volume (30 Days) | 98.2K | ★ 2.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,001,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $0.64 |
| 52 Week High | $19.01 | $7.29 |
Technical Indicators
Market Signals| Indicator | BRT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 40.44 |
| Support Level | $14.18 | $0.69 |
| Resistance Level | $15.33 | $0.83 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 9.54 | 19.94 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.